| Identification | Back Directory | [Name]
erythromycin aspartate | [CAS]
30010-41-4 | [Synonyms]
erythromycin aspartate
Erythromycin L-aspartate | [Molecular Formula]
C37H67NO13.C4H7NO4 | [MDL Number]
MFCD01744427 | [MOL File]
30010-41-4.mol | [Molecular Weight]
867.033 |
| Hazard Information | Back Directory | [Uses]
Erythromycin aspartate is a macrolide antibiotic produced by actinomycete?Streptomyces erythreus?with a broad spectrum of antimicrobial activity. Erythromycin aspartate binds to bacterial 50S ribosomal subunits and inhibits?RNA-dependent protein synthesis?by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1][2]. Erythromycin aspartate also exhibits antitumor and neuroprotective effect in different fields of research[3][4]. | [in vivo]
Erythromycin aspartate (gastric intubation; 0.1-50 mg/kg; 30-120 days) decreases tumor growth and prolong the survival time of mice from dose of 5 mg/kg in mice[3].
Erythromycin aspartate (gastric intubation; 5 mg/kg) protects mice alive even at 120 days after inoculation, but shortens mean survival time in tumor-bearing mice by 4-5 days with dose of 50 mg/kg[3].
Erythromycin aspartate (i.h.; single injection; 50 mg/kg) has a protective effect on the rat model with cerebral ischemia reperfusion-injury[4].
| Animal Model: | Female ddY mice (6-week-old) with EAC cells or CDF mice (6-week-old) with P388 cells[3] | | Dosage: | 0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg
| | Administration: | Gastric intubation; 30-120 days
| | Result: | Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortened the MST in tumorbearing mice.
|
| Animal Model: | Male Sprague-Dawley rats (8-week-old, 250-300 g)[4] | | Dosage: | 50 mg/kg
| | Administration: | Subcutaneous single injection
| | Result: | Reduced infarct volume and edema volume, improved neurological deficit.
|
| [IC 50]
Macrolide | [References]
[1] Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89. DOI:10.1016/s0025-7125(16)31443-2
[2] Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec. 100(3):185-91. DOI:10.1016/j.actatropica.2006.10.008
[3] Hamada K, et al. Antitumor effect of erythromycin in mice. Chemotherapy. 1995 Jan-Feb. 41(1):59-69. DOI:10.1159/000239325
[4] Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67. DOI:10.1016/j.brainres.2014.09.016 |
|
|